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Objectives:
 
 This analysis estimated the direct cost of
rheumatoid arthritis (RA) from a societal perspective.
 
Methods:
 
 Primary and secondary data sets were used to
determine the rate of medical resource utilization. Na-
tional average Medicare or Medicaid reimbursement
rates were used to value direct costs (in 1994 dollars).
 
Results:
 
 Persons with RA have, on average, $1702 in
direct costs for treating RA annually. More than half of
the total cost is for medications. Nursing home care ac-
counts for nearly one fifth of the cost and hospitaliza-
tions and ambulatory care (combined) comprise another
fifth of the total cost. Travel to medical appointments
and medical supplies make up the remaining 10%. The
projected annual US direct costs are $3.6 billion for
treating RA.
 
Conclusions:
 
 The health care utilization in persons with
RA is frequent and includes a number of components
leading to high annual direct cost.
 
Keywords:
 
 cost of illness, direct cost, medical resource
utilization, rheumatoid arthritis.
 
Introduction
 
Rheumatoid arthritis (RA) is estimated to affect
roughly 1.1% of the adult population [1], or more
than 2.1 million US adults. The age of onset is
commonly in the 40s and most afflicted individu-
als require medical treatment for decades. Because
of its chronic, progressive nature and the number
of people affected, RA may be among the most
costly disorders.
The published literature contains a number of
studies of the cost of various components of treat-
ing RA (e.g., hospitalization). These studies have
produced a range of estimates, probably because
they used a variety of methodologies. First, this lit-
erature includes studies in samples of people who
are known to have RA [2–6] along with population
estimates based on encounter data [7–9]. Second,
some of the reported costs are for the treatment of
RA-related complaints only [2,3,5,8–10] and oth-
ers are for the treatment of all conditions in persons
known to have RA [4,7,11]. Third, although al-
most all of the studies refer to costs, in fact, none of
them actually reports costs of providing medical
treatment. Instead, one uses Medi-Cal reimburse-
ments [7], one uses Medicare reimbursement [8],
two use an average of estimates from the literature
[9,12], and the majority use charges or billed values
[2,3,5,6,8,11], usually from a single institution.
Estimates of the total cost of treating persons
with RA are also limited. The per-person total direct
cost of RA is available from six studies [2–4,7,8,11].
However, in three of these studies, the cost-of-illness
calculations were made in databases collected prior
to 1982 [2,3,7]. A more recent paper [12] projected
data from three of these earlier studies [2,3,7] to
1991 dollars using price adjustments; however, no
new data were reported.
The more recent three papers [4,8,11] used dif-
fering approaches to determine utilization and
cost. One study [8] determined per-patient cost for
members of a health maintenance organization
(HMO) and computed the cost-of-illness in 1994
for that HMO. The second study [11] computed
per-patient cost and the cost-of-illness on 1987
data from all prevalent cases in a single county.
Both established inclusion/exclusion rules for identi-
fying persons with RA based on previous visits
where RA was coded as the diagnosis for an encoun-
ter. The third study [4] used a longitudinal panel
to determine per-patient cost and cost-of-illness in
1995–96. These three studies also differ in their cost-
ing approach and findings. The first study [8], using
Medicare reimbursements, estimated per-person di-
rect costs at $2162. The second study [11], using
charges, estimated per-person direct costs at $3802.
And the third study [4], using a combination of
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Medicare reimbursements and charges, estimated
per-person direct cost at $5919 per year.
Because of the spread of these estimates, we un-
dertook an analysis to attempt to rectify the differ-
ences among these studies. To do so, we used esti-
mates derived from the longitudinal panel used in
the third study [4]. In addition, we developed esti-
mates using surveys conducted by the National Cen-
ter for Health Statistics of medical resource utiliza-
tion. Where possible, estimates from both sources
were compared. Also, to make the estimates more
comparable, we applied Medicare reimbursement
rates to all components of utilization (the previous
study using this panel had used a combination of
Medicare and charges). Finally, we use cost-to-charge
ratios to permit comparisons among studies.
 
Materials and Methods
 
Approach
 
This article adopts a limited societal perspective to
estimate the direct cost of RA. It is limited in that
indirect costs are not included. Direct costs in-
clude the major components of medical resource
utilization—hospitalization, outpatient physician
visits, visits to other health care professionals,
transportation to medical appointments, medica-
tion, medical devices, and nursing home care.
For the direct costs, ideally we would value
these using the national average cost of delivering
these medical services. However, even on a limited
local basis, cost is difficult to estimate [13–15] and
certainly no national average exists. Consequently,
we have valued direct costs using Medicare and
Medicaid reimbursement rates. Of course Medi-
care and Medicaid are not the only payer for ser-
vices to persons with RA. However, we have used
these reimbursement rates as a means to value cost
because these represent a reasonable proxy for the
long-run opportunity costs of medical and nursing
home care. Thus, for the present article, hospital-
ization, outpatient visits, and medical devices were
valued using national average Medicare reimburse-
ment rates. Medications were valued at median
average wholesale price (AWP) and transportation
was valued at federally specified mileage reim-
bursement rates. Nursing home care was valued
using Medicaid reimbursement rates, which are
comparable to Medicare rates, but much more
common as the source of payment. When we use
the term 
 
cost
 
, it refers to these reimbursement
rates.
Per-person annual utilization rates were deter-
mined separately for males and females and six
age groups (25–34, 35–44, 45–54, 55–64, 65–74,
and 75
 

 
). The previous studies used utilization
and cost data from 1987 [11], 1994 [8], and
1995–96 [4]. To facilitate comparisons, per-per-
son annual utilization was determined from the
data that were available for the years closest to
this range, then costs in 1994 dollars were deter-
mined, and prevalence figures by age and gender
were used to project the total annual cost to the
US adult population with RA in 1994.
 
Sample Selection and Epidemiology
 
The most common forms of RA are captured in
ICD-9 codes 714.0–714.2, 714.8, and 720. Juve-
nile rheumatoid arthritis (ICD-9 code 714.3) dif-
fers in several ways from adult-onset RA and was
excluded from the current analysis. The preva-
lence rates for RA are based on the National
Health Examination Survey [16], as modified by
the National Arthritis Data Workgroup [1]. These
prevalence rates were multiplied by the US census
figures in 1994 [17] to estimate the number of
adults in the US population meeting criteria for
definite or classical RA. As shown in Table 1,
there are an estimated 2.1 million adults in the US
with RA.
 
Data Sources
 
To calculate the cost of illness of RA, estimates of
all components of medical care were necessary. As
described below, some estimates were derived
from a large primary panel of persons with RA
and others were derived from secondary analyses
of surveys conducted by the National Center for
Health Statistics.
The primary panel of persons with RA is
known as the UCSF RA Panel Study. The RA
Panel Study began in 1982 and 1983 when a ran-
dom sample was selected of half of the 114 board-
 
Table 1
 
RA prevalence rates and current US population 
with RA
 
RA prevalence 
rates
Current US population 
with RA
Age in years Men Women Men Women
18–24 0.0 0.0 0 0
25–34 0.0 0.0 0 0
35–44 0.0 0.9 0 188,000
45–54 0.2 1.1 28,000 164,000
55–64 1.9 2.9 191,000 323,000
65–74 1.8 4.9 150,000 513,000
75
 

 
1.8 4.9 93,000 452,000
Total N/A N/A 462,000 1,640,000
 
RA, rheumatoid arthritis.
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certified rheumatologists then listed in Northern
California, incorporating the area from Monterey
County to the Oregon border. Of the 57 rheuma-
tologists included in the sample, 7 reported no pa-
tient care activities and 10 declined to participate.
The remaining 40 rheumatologists maintained a
log of all persons meeting criteria for RA present-
ing to their offices during a 1-month period, com-
pleted a questionnaire about their training and
practice, and provided standard measures of the
severity of each person’s RA. The physicians listed
847 persons, of whom 822 were enrolled.
In 1989, to increase the panel, a random sample
of 11 rheumatologists was selected from among
all those who were board certified and who had
not been included in the original 57. Of these 11
physicians, 10 agreed to participate. These 10
rheumatologists again maintained logs of all persons
with RA presenting to their offices over a 1-month
period, providing the names of 215 persons with
RA, of whom 203 were enrolled.
Over the two cycles of enrollment, 1025 per-
sons with RA (96.5%) were enrolled from among
the 1062 eligible for the study. All patients met
American College of Rheumatology (ACR) classi-
fication criteria for RA. As of the end of 1993, the
RA Panel Study had accumulated 7485 person-
years of follow-up on these 1025 individuals.
The principal data collection method for the
RA Panel Study is an annual, structured telephone
interview conducted by a trained survey worker.
The interview covers basic demographic informa-
tion, signs and symptoms of RA, extent of comor-
bidity and overall health status, functional status,
and an inventory of health care utilization for RA
and other reasons in the year before the interview.
For the health care utilization questions, the study
respondents report the number of physician visits
they made for RA and non-RA reasons according
to physician specialty in the year before being in-
terviewed. Similarly, they report the number of
hospital admissions for RA and non-RA reasons.
For each RA-related admission, the person is asked
about the content of the admission, including all
surgical procedures performed. Respondents are
also asked about visits to other health care profes-
sionals and about any medication taken for RA.
Many of the specific health care utilization items
were adapted from the National Health Interview
Survey and were validated for inclusion in that
survey [18]. Periodic supplements have assessed
transportation costs to medical appointments and
use of medical or support equipment. Where utili-
zation data were available annually, 10 years of
data (1984–93) were averaged to derive stable es-
timates. The validity of this self-report data was
checked by comparison of hospitalization recall
with hospital records of the number, length, and
content of admissions in a random sample and
only a small rate of error in patient reporting was
found [19].
Large national surveys are conducted by the
National Center for Health Statistics to cover nearly
all components of medical resource utilization. For
example, the National Hospital Discharge Survey
(NHDS) samples discharges from a random sam-
ple of hospitals [20]. The National Ambulatory
Medical Care Survey (NAMCS) collects basic de-
mographic, diagnostic, and procedural information
on all outpatients seen in a 1-week period by a
random sample of physicians practicing in nonin-
stitutional single and small-group practices [21].
The National Hospital Ambulatory Medical Care
Survey (NHAMCS) collects the same information
on patients seen by physicians practicing in hospi-
tal-based practices [22]. The National Nursing
Home Survey (NNHS) provides information of
nursing home utilization [23]. The NHDS and
NAMCS are conducted annually, the NHAMCS
and NNHS are conducted every few years. In these
surveys, respondents are assigned weights so that
inferences can be drawn about the entire US popu-
lation. In addition to analyzing these data to iden-
tify the types and duration of services provided,
Medicare Part B Public Use Files were analyzed to
identify physician, diagnostic imaging, radiology,
and laboratory services that were matched to hos-
pitalizations by diagnosis related group (DRG).
The sources of data for each component of uti-
lization and valuation are shown in Table 2. Spe-
cific methods used to determine medical resource
utilization rates and valuations for each compo-
nent of care are described below. Unfortunately,
in the years sampled, neither the UCSF panel nor
the national public use data sets included informa-
tion on several components of care including
home care, home modifications, outpatient labo-
ratory, and diagnostic radiology tests. Consequently,
these components of the direct cost of RA could
not be determined.
 
Hospitalizations
 
The number of hospitalizations was computed us-
ing both the NHDS and the UCSF RA Panel. For
the NHDS, 2 years worth of data were combined
and analyzed to increase the stability of estimates.
Hospitalizations were valued at national average
Medicare DRG reimbursement rates [24].
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Analyses of the NHDS consisted of two compo-
nents. First, hospitalizations for which RA was the
principal diagnosis were identified. DRGs were
used to value these hospitalizations. Second, an in-
vestigation was conducted to determine whether
RA patients were hospitalized for longer (or shorter)
periods than other gender- and age-matched patients
for a given DRG. To do so, the length of actual hos-
pitalization for patients with RA was subtracted
from the published average number of days of hospi-
talization for each DRG [24]. The difference in
length of stay was valued at 60% of the daily Medi-
care reimbursement rate, consistent with Medicare
policy for reimbursing excessive lengths of stay
(later days of hospitalization are less costly than ear-
lier days when service is typically more intensive).
Costs associated with hospitalizations for which
RA was the principal diagnosis and the costs asso-
ciated with extra days of stay for hospitalizations
in patients with RA were added together to obtain
the hospitalization costs attributable to RA. DRG
reimbursements cover only the facility portion of
hospitalizations. To value the component of hos-
pitalizations covered under Medicare Part B (e.g.,
physician services, laboratory costs), the Medicare
Public Use Files were used to determine the allow-
able Medicare charges for physician services asso-
ciated with hospitalization. Allowable Medicare
charges for physician services were matched to
hospitalizations and the average allowable charges
were calculated by DRG. These were added to the
DRG reimbursement rates to create a total reim-
bursement rate for hospitalizations.
In the UCSF RA Panel, the RA sample was in-
terviewed annually and asked to recount all hospi-
talizations in the previous year and to designate
for each hospitalization whether it was for a rea-
son related to their RA. The number of hospital-
izations listed in each of the past 10 years was av-
eraged to determine the rate of hospitalizations
per year (by gender and six age groups) in this
sample of persons with RA. This distribution of
rates of hospitalizations was multiplied by the
number of US adults projected to have RA based
on the prevalence figures, to yield the projected
number of US hospitalizations for persons with
RA. These hospitalizations were valued by multi-
plying the rate by the average total Medicare reim-
bursement rate, derived above, for each age and
gender cell.
 
Outpatient Physician Visits
 
The number of outpatient physician visits for pa-
tients with RA was computed from three sources:
the NAMCS, the NHAMCS, and the UCSF RA
Panel. In the NHAMCS, only 1 year of data was
available, but in the NAMCS, 3 years worth of
data were combined and analyzed to increase the
stability of estimates. The number of outpatient
physician visits was computed for visits where RA
was the first-, second-, or third-listed diagnosis. In
the UCSF RA Panel, outpatient physician visits for
which the patient attributed the visit to RA were
tabulated in each of the previous 10 years and av-
eraged to compute an average annual rate of visits.
Outpatient physician visits were valued at na-
tional average Medicare reimbursement rates. Visits
to physicians are reimbursed by Medicare on the ba-
sis of current procedural terminology (CPT) codes
which reflect the duration of visit and whether the
patient is new to the practice or established. Each
visit in the NAMCS and NHAMCS was assigned
the appropriate Medicare reimbursement rate based
on duration of visit and status of patient—new
or established [25]. The average reimbursement
amount for each cell (by age, gender) from the
NAMCS was applied to the same cell in the UCSF
RA Panel to value these outpatient physician visits.
 
Table 2
 
Sources of data
 
Type of utilization Source of data to estimate utilization Source of data for valuation
Hospitalization 1992 and 1993 NHDS Medicare DRG
1984–93 UCSF RA Panel
Inpatient physician/laboratory/diagnostic imaging 1993 Medicare Part B Medicare allowable charges
Outpatient physician visits 1991–93 NAMCS Medicare CPT
1992 NHAMCS
1984–93 UCSF RA Panel
Outpatient nonphysician visits 1984–93 UCSF RA Panel Medicare CPT
Transportation 1990 UCSF RA Panel Federal rate of reimbursement for mileage
Medical devices 1984–93 UCSF RA Panel Medicare HCPCS
Medication 1984–93 UCSF RA Panel Average wholesale price
Nursing home care 1985 NNHS Medicaid
 
CPT, current procedural terminology; DRG, diagnosis-related group; HCPCS, HCFA Common Procedure Coding System; NAMCS, National Ambulatory Medical
Care Survey; NHAMCS, National Hospital Ambulatory Medical Care Survey; NHDS, National Hospital Discharge Survey; NNHS, National Nursing Home Survey.
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Outpatient Visits to Other Health Care Professionals
 
In the UCSF Panel, the RA sample was inter-
viewed annually and asked about visits to other
health care providers in the previous year. The re-
sponse options were: physical or exercise thera-
pist, chiropractor, occupational therapist or voca-
tional counselor, nurse or nurse practitioner,
social worker, or other health provider (psycholo-
gists or psychiatrists, acupuncturist, and homeo-
pathic or holistic specialists). The number of visits
to each of these providers for RA-related reasons
in each year was averaged to determine the num-
ber of such visits per year. Each visit was valued
using the appropriate Medicare reimbursement
rate [26]. Physical or exercise therapists, occupa-
tional therapists or vocational counselors, and chi-
ropractors can bill Medicare directly. Nurses or
nurse practitioners usually provide service to RA
patients incident to a supervising physician and
bill at the physician’s rate. The few visits to social
workers and nonphysician health care providers
not already mentioned were valued at the Medi-
care reimbursement rate applicable to nurses.
 
Transportation to Medical Appointments
 
In the annual interview of the UCSF RA Panel in
1990, the respondents were asked about their
mode of transportation and the travel time to
medical appointments. The projected number of
visits attributable to RA (outpatient physician vis-
its and visits to other health care providers for
treating RA) was multiplied by the reported aver-
age distance to medical appointments and was val-
ued using the federally specified rate of reimburse-
ment for mileage.
 
Medications
 
In the UCSF RA Panel, the RA sample was inter-
viewed annually and asked to recount all medica-
tions taken in the previous year. The number of
specific brand and generic medications in each
year was averaged to determine the rate of each
type of medication per year. For each brand or
formulation the anti-inflammatory dose range or
the usual dose range for RA was determined from
the Handbook of Drug Therapy in Rheumatic
Diseases [27]. The average number of days of
medication use in the previous year per person
was derived as the product of the percentage of
the panel who took the medication in the previous
year and the estimate of the number of days on av-
erage that they took the medication. Even though
most oral medications are not covered by Medi-
care, we used Medicare reimbursement policies to
value all drugs so that the valuation scheme was
consistent across this analysis. For the drugs that
Medicare does cover, it reimburses at the median
level of AWP for generics, and at AWP for brand-
name drugs if generics are not available [28]. The
per-person yearly valuation of medication was de-
rived as the product of the AWP cost per day for
medication users and the estimated average num-
ber of days of medication use per person.
 
Medical Equipment and Devices
 
In the UCSF RA Panel, the RA sample was inter-
viewed annually and administered the Health As-
sessment Questionnaire (HAQ), which includes
questions on whether the respondent currently
uses specific medical equipment and devices be-
cause of their RA, including wheelchairs, canes,
crutches, or walkers. The percentage of respon-
dents indicating that they used each of these de-
vices in each year was averaged to determine the
prevalence of use of these devices annually. Each
device was assigned a Health Care Financing Ad-
ministration (HCFA) common procedure coding
system (HCFA Common Procedure Coding Sys-
tem [HCPCS] Level II) code [29] and was valued us-
ing the appropriate Medicare reimbursement rate.
 
Nursing Home Care
 
Nursing home stays were estimated in the 1985
NNHS by identifying those persons who had a
primary diagnosis of RA [23]. Medicaid (rather
than Medicare) is the primary payer for nursing
home stays, so nursing home care was valued us-
ing annual Medicaid reimbursement rates.
 
Results
 
Hospitalizations
 
The annual number of hospitalizations for the na-
tional population of US residents with RA, com-
puted using both the NHDS and the UCSF RA
Panel, yielded 1 million hospitalizations. Analysis
of length of stay in the NHDS indicated that hos-
pitalizations for which RA was the principal diag-
nosis were generally for shorter durations than
hospitalizations for which RA was not a principal
diagnosis (after adjusting for type of DRG, and
the age and gender of the patient). This pattern
probably occurred because (1) the surgical DRGs
for first-listed RA (primarily DRG 209) are elec-
tive when RA is involved, but are more likely to be
the result of traumatic injury when RA is not in-
volved; and (2) the medical DRGs (primarily
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DRGs 240 and 241) may be less severe when due
to first-listed RA as opposed to other connective
tissue disorders. In contrast, hospitalizations for
which RA was an other-listed diagnosis were gen-
erally for longer durations than hospitalizations
for the same DRG in persons without RA. As
shown in Table 3, the annual rate of hospitaliza-
tions attributed to RA was 0.15 annually per per-
son. On a per-person basis, the average annual
cost of hospitalizations attributable to RA was
$210, as shown in Table 4.
All costs associated with hospitalizations for
which RA was the principal diagnosis and the cost
adjustments associated with lengthier hospitaliza-
tions for which RA was an other-listed diagnosis
were added together to obtain the hospital costs
attributable to RA: $339 million. Analysis of
Medicare Part B indicated that the inpatient physi-
cian/lab costs attributable to RA were estimated to
be $101.8 million. As shown in Table 5, the sum
of these was $440.8 million.
 
Outpatient Physician Visits
 
The number of outpatient physician visits attrib-
utable to RA, computed from the NAMCS/
NHAMCS and the UCSF RA Panel, were averaged
and yielded 7.0 visits annually for RA, as shown in
Table 3. The number of outpatient physician visits,
projected to the US population with RA, yielded
32.6 million visits annually for a total cost of $293
million, as shown in Table 5. On a per-person ba-
sis, RA-associated outpatient physician visits aver-
aged $139 annually, as shown in Table 4.
 
Outpatient Visits to Other Health Care Professionals
 
The number of visits to other health care provid-
ers for RA-related reasons for the national popula-
tion of US residents with RA was calculated from
the UCSF RA Panel. Results indicated that the
annual numbers of visits to physical therapy pro-
viders (i.e., physical or exercise therapist, chiro-
practors, occupational therapists or vocational coun-
selors) was 2.0 and the annual number of visits to
nurses or nurse practitioners, social workers, or
other allied health care providers was 2.2, as
shown in Table 3. The results, projected to the US
population with RA, yielded 4.2 million visits to
physical therapy providers and 4.5 million visits
to nurses and other allied health care providers
annually for a total cost of $160.8 million, at-
tributable to RA, as shown in Table 5. On a per-
person basis, the average annual cost was $77, as
shown in Table 4.
 
Transportation to Medical Appointments
 
As shown in Table 3, the average number of per-
person outpatient visits to physicians and visits to
other health care providers for treatment of RA
was 11.2. Using the UCSF RA Panel to determine
transportation costs, this projected number of vis-
its to physicians and other health care providers
resulted in an annual cost of $89 million of trans-
portation costs attributable to RA (shown in Ta-
ble 5). On a per-person basis, the average cost of
transportation to RA-associated medical appoint-
ments was $42 (shown in Table 4).
 
Medications
 
The per-person yearly valuation of medication
was derived from the UCSF RA Panel as the prod-
uct of the AWP cost per day for medication users
and the estimated average number of days of med-
ication use per person. The estimated yearly cost of
 
Table 3
 
Average per-person annual rate of medical 
resource utilization (except medication) attributable to RA
 
Type of utilization
Rate attributable
to RA
Hospitalization 0.15
Outpatient physician visits 7.00
Outpatient nonphysician visits 4.22
Transportation (round trips) 11.22
Medical devices 0.30
 
RA, rheumatoid arthritis.
 
Table 4
 
Annual per-person direct costs attributable to RA
 
Type of cost Cost ($) %
Hospitalization 210 12.3
Outpatient physician visits 139 8.2
Outpatient nonphysician visits 77 4.5
Transportation to appointments 42 2.5
Medication 918 53.9
Medical devices 10 0.6
Nursing home care 306 18.0
Total direct costs 1702 100
 
RA, rheumatoid arthritis.
 
Table 5
 
Annual US direct cost attributable to RA
 
Type of cost Cost ($ 
 

 
 10
 
6
 
)
Hospitalization 441
Outpatient physician visits 293
Outpatient nonphysician visits 161
Transportation to appointments 89
Medication 1992
Medical devices 21
Nursing home care 642
Total direct costs 3639
 
RA, rheumatoid arthritis.
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medication attributable to RA is nearly $2 billion
(shown in Table 5), which includes $652 million
for nonsteroidal anti-inflammatory drugs, $1.2
billion for disease-modifying antirheumatic drugs
(DMARDs), and $52 million for corticosteroids.
The cost of medication for RA averaged $918 per
person annually (shown in Table 4).
 
Medical Equipment and Devices
 
The annual prevalence for use of medical equipment
and devices was 30% (7.2% for wheelchairs, and
23.0% for canes, crutches, or walkers), projected
from the UCSF RA Panel (shown in Table 3). These
figures, projected to the US population with RA,
suggest that 151,000 persons with RA use wheel-
chairs and 484,000 persons with RA use canes,
crutches, or walkers, for a total annual cost of $21.2
million attributable to RA (shown in Table 5). The
cost of medical equipment and devices for RA aver-
aged $10 per person annually (shown in Table 4).
 
Nursing Home Care
 
According to the NNHS, the proportion of persons
in nursing homes whose primary diagnosis is RA is
1.4% of current residents. Using this estimate, the
cost of nursing home stays attributable to RA
would be $642 million at Medicaid reimbursement
rates (shown in Table 5). On a per-person basis,
RA-associated nursing home expenses would be
estimated at $306 (shown in Table 4).
 
Summary of Annual Direct Costs in Persons with RA
 
The per-person direct cost attributable to RA is
shown in Table 4, along with the percentage of
the total direct costs for each component of cost.
In terms of costs attributable to RA, the annual
per-person cost of hospitalizations ($210) is equal
to the cost of outpatient care ($139 to physicians
and $77 to other health care providers), and 50%
less than the cost of nursing home care ($306). By
far the largest component of cost for persons with
RA is medication ($918), which accounts for more
than half of the total direct costs ($1702).
The annual direct cost of RA projected to the
US population is summarized in Table 5. These to-
tal $3.6 billion in health care costs directly associ-
ated with RA.
 
Discussion
 
The results of this analysis indicate that persons
with RA incur an average of $1702 in medical ex-
penses per year, in 1994 dollars, on a per-person
basis, if Medicare/Medicaid reimbursement rates
are used to value direct costs. To put these results
in perspective, they are first compared to compa-
rable findings in the literature, and then the effects
of sensitivity analyses are discussed.
 
Comparison of Current Estimates with the Literature
 
Analysis of the NHDS found an annual rate of
0.19 for hospitalizations where RA was listed as a
diagnosis, and the analyses of the UCSF RA Panel
found an annual hospitalization rate of 0.15 at-
tributable to RA. Earlier estimates from the UCSF
RA Panel in 1982–83 [19] found an annual hospi-
talization rate of 0.23 for treating RA. This find-
ing suggests a slight decrease over the past 15
years in the annual rate of RA-related hospitaliza-
tions. In addition, the cause of hospitalizations ap-
pears to have changed. The NHDS indicated that
63% of the hospitalizations where RA was the
first-listed diagnosis were for surgical DRGs, in
comparison to 1981 estimates of one-third to one-
half [5]. These findings suggest a dramatic trend
away from medical hospitalizations and toward
surgical hospitalizations in patients with RA.
The current study estimated an annual visit rate
of 7.0 when the numbers of visits for RA from
analysis of the NAMCS and NHAMCS were aver-
aged with the numbers of RA-related visits from
the UCSF Panel study. Estimates from previous
studies [2,3,8,10,28,30,31] average 9.6, suggest-
ing that the number of outpatient physician visits
has decreased. However, the possibility that the
current figures underestimate the actual rate of
visits cannot be dismissed, given that the NAMCS
and NHAMCS may have incomplete attribution
of diagnoses.
We also compared the current per-person direct
cost to the three recent estimates in the literature
[4,8,11]. These three studies differ in their costing
approach and findings. The first study [8], using
Medicare reimbursements, estimated per-person
direct costs at $2162. The second study [11], us-
ing charges, estimated per-person direct costs at
$3802. And the third study [4], using a combina-
tion, estimated per-person direct costs at $5919
per year.
Charge data are variably [14] inflated over the
cost of delivering health care, dependent on the
rate of nonpayment, discounts, and inefficiencies
or profit margins in the system [15]. In the United
States, these factors, especially the rate of uncol-
lectibles, leads to a high inflation of charges for
some institutions. To compare the current findings
with the literature, the previously published values
based on charges were multiplied by 0.43 (the ra-
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tio of Medicare reimbursements to charges for
hospitalizations and inpatient physician services
determined in the current analysis) to permit com-
parisons with the current values, which are based
on national average Medicare reimbursement rates.
Using this adjustment, the total per-person direct
cost for RA would be $1635 [11], $2162 [8], and
$4123 [4] in the literature, compared to the cur-
rent estimate of $1702.
 
Potential Limitations
 
The most obvious limitation of the current study
is the lack of availability of new data on several
components of care, including home care, home
modifications, outpatient laboratory, and diagnos-
tic radiology tests. Using estimates from the litera-
ture [32], we estimate the cost of home care to be
$200 per person per year and the cost of home
modifications to be $200 per person per year. Ex-
trapolating these to the US population would sug-
gest that the total cost of illness for RA should be
$800 million higher.
In terms of laboratory tests and diagnostic radi-
ography, we analyzed the 1992 NHAMCS [22],
but the number of cases identified with RA who
had data on lab tests was too few to yield reliable
estimates. Looking to the literature, previous esti-
mates of the average annual expenditures for labo-
ratory tests were $527 and for radiographs were
$282 in one study [3] and totaled $277 in another
[4]. Using the average from these studies to esti-
mate the laboratory and radiography expenditures
at $340 per RA patient, total costs for this compo-
nent would be approximately $700 million.
A further potential limitation of the present
study is the reliance on the UCSF RA Panel for
much of the analysis. Most data from this panel
were averaged over 10 years to increase stability,
but there remains the possibility of nongeneraliz-
ability of any geographically restricted database.
Mitigating this concern is the fact that participants
in this panel cover a 5000-square-mile area and
receive care from numerous providers. Indeed, the
utilization estimates from this panel agree quite
closely with estimates in the literature from a
range of other sources, suggesting good generaliz-
ability.
A second potential limitation of using the UCSF
RA Panel in this type of analysis is that the panel
was constructed for longitudinal studies, which
means that the sample has aged over time and
their RA has likely progressed. We averaged utili-
zation over a 10-year period in an attempt to in-
crease stability and average across persons with
different disease severity. However, because this
sample was recruited from rheumatologists and
followed for 10 years, their disease severity may
be greater than a cross section of all persons with
RA. The earlier years sampled may partially ex-
plain the difference in cost estimates between the
current study and an estimate based on the same
database using later years [4].
Another potential problem with the data from
the UCSF RA Panel is that the data are collected
during annual telephone interviews and are thus
subject to recall bias. An independent check of the
hospitalization recall was done with chart review
[19] and the hospital utilization rate from the
UCSF RA Panel agreed closely with the literature
and NHDS estimates. However, other compo-
nents of utilization were not similarly checked and
recall bias could be greater for nonhospital events.
 
Sensitivity Analysis
 
The results of this analysis suggest that persons
with RA incur an average of $1702 in medical ex-
penses per year as a direct result of having RA.
For the over 2 million adults in the United States
who have RA, medical expenses total $3.6 billion
directly for treating RA. These values may be un-
derestimated by as much as $1.5 billion in home
care, home modifications, and laboratory costs,
which could not be determined with available
data sets.
Sensitivity analyses were used to estimate other
areas of uncertainty. One factor subjected to sensi-
tivity analysis was the cost of medication. In the
current analysis, the annual per-person cost of
medication was estimated to be $918. This figure
is calculated based on assumptions of full compli-
ance. Estimates from the literature have found
that compliance rates for chronic disorders con-
verge around 50% of prescribed quantities [33–36]
regardless of the illness or setting [36], and that
persons with RA have been found to decrease com-
pliance over time [37]. Using these estimates from
the literature, the cost of medications for RA in
the United States would decrease to $1.5 billion if
compliance was 75% and to $1.0 billion if com-
pliance was 50%.
Sensitivity analyses were also conducted to esti-
mate the effect of payment from sources other than
Medicare/Medicaid. Assuming private insurance re-
imbursement rates currently cover (either directly or
via cross-subsidization) approximately half of the
medical expenses in persons with RA, the RA-associ-
ated medical care cost estimates (excluding transpor-
tation and medication) could be increased by $779
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million over the estimates reported here, which were
based on Medicare reimbursement rates.
In summary, estimates from the current study
indicate that the direct cost of treating RA in the
United States is $3.6 billion. Clearly, both the rate
of utilization and cost of treating RA are high.
Persons with RA have been estimated to have
health care costs 2 [38] to 3 [11] times the rate of
persons without RA. This makes RA a prime can-
didate for efforts to develop new treatments that
will improve health outcomes and decrease medi-
cal care costs.
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